Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Fabrazyme
Active Ingredient: Agalsidase beta - rch 5.5mg
Dosage Form: Powder for infusion concentrate
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited (trading as Healthcare Logistics)
Manufacturer: Genzyme Corporation, Allston, Massachusetts, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 12th day of October 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).